Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 3/20 | 0.60 |
| ▸ | MMP2 | P08253 | 3/20 | 0.42 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | MMP14 | P50281 | 5/20 | 0.41 |
| ▸ | MMP8 | P22894 | 4/20 | 0.41 |
| ▸ | MMP17 | Q9ULZ9 | 3/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135513 | 1.00 | ADAM17 (0.60) | ADAM17MMP2ADAMTS5MMP13MMP14 | |
| SCHEMBL3410690 | 1.00 | ADAM17 (0.60) | ADAM17MMP2ADAMTS5MMP13MMP14 | |
| SCHEMBL20135452 | 0.86 | ADAM17 (0.57) | ADAM17MMP2ADAMTS5MMP13MMP14 | |
| SCHEMBL11092735 | 0.84 | MMP2 (0.51) | ADAM17MMP2MMP3 | |
| SCHEMBL3412312 | 0.84 | ADAM17 (0.44) | ADAM17MMP2MMP3 | |
| SCHEMBL2191989 | 0.84 | ADAM17 (0.62) | ADAM17MMP2 | |
| SCHEMBL4123231 | 0.84 | ADAM17 (0.62) | ADAM17MMP2 | |
| SCHEMBL3400918 | 0.84 | ADAM17 (0.62) | ADAM17MMP2 | |
| SCHEMBL20135014 | 0.83 | ADAM17 (0.55) | ADAM17MMP2ADAMTS5MMP13MMP14 | |
| SCHEMBL542857 | 0.81 | TNF (0.50) | ADAM17MMP2ADAMTS5MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922347-B | Novel imide derivatives and their use as pharmaceuticals | 田边三菱制药株式会社 | 2022-06-28 | — | — | CN | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | ADAM17 36/4885MMP2 4/4885ADAMTS5 23/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | ADAM17 39/4885MMP2 2/4885ADAMTS5 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.